Clinical Study on the Effectiveness and Safety of Guanxinning Tablets on Coronary Heart Disease Complicated with Diabetic Nephropathy

Affiliated Hospital of Hangzhou Normal University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•(1) Meet the diagnostic criteria of blood stasis syndrome of coronary heart disease (Diagnostic criteria of blood stasis syndrome of coronary heart disease);
•(2) Meet the diagnostic criteria for diabetes (diabetes mellitus, DM) established by the ADA in 2020;
•(3) Those who meet one of the following conditions (Chinese Guidelines for Clinical Diagnosis and Treatment of Diabetic Kidney Disease 2021):
•?Random urinary albumin/creatinine ratio (UACR) = = CR or urinary albumin excretion rate (UAER) = = R white excretion rate (( sugar, and repeat check UACR or UACR within 3-6 months) UAER, 2 out of 3 times reached or exceeded the critical value.
•?Estimate the glomerular filtration rate (eGFR) <60ml glomerular filtration rate (. Sugar 3m-2, more than 3 months.
•?Kidney biopsy conforms to the pathological changes of diabetic kidney disease (DKD).
•(4) Those aged =18 years, =, =years old;
•(5) Subjects are informed and voluntarily sign an informed consent form.

•(1) Does not meet the inclusion criteria;
•(2) People with infection, fever, congestive heart failure, uncontrolled blood sugar and blood pressure, or urinary tract infection;
•(3) Unwilling to cooperate and mentally ill patients;
•(4) Patients with serious diseases such as heart, lung, brain, liver, kidney, hematopoietic system, etc.;
•(5) ALT and AST are higher than 3 times the upper limit of the normal range;
•(6) Patients who have participated in clinical trials of other drugs in the past month;
•(7) Women who are pregnant or preparing to become pregnant or breast-feeding;
•(8) Those who have a history of drug allergy or allergic physique and are allergic to multiple drugs;
•(9) Other patients who do not meet the selection criteria as judged by the investigator.

发起方

Affiliated Hospital of Hangzhou Normal University